Literature DB >> 18637146

Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice.

Yuko Nakanishi1, Koichi Tsuneyama, Kazuhiro Nomoto, Makoto Fujimoto, Thucydides L Salunga, Takahiko Nakajima, Shigeharu Miwa, Yoshihiro Murai, Shinichi Hayashi, Ichiro Kato, Koichi Hiraga, Daniel K Hsu, Fu-Tong Liu, Yasuo Takano.   

Abstract

AIM: Nonalcoholic fatty liver disease (NAFLD) represents a growing health concern due to its rapidly increasing prevalence worldwide. Nonalcoholic steatohepatitis (NASH) is a progressing form of NAFLD, and recently many studies have reported that it could eventually develop into hepatocellular carcinoma (HCC). We previously reported that 6-month-old male galectin-3 knockout (gal3(-/-)) mice developed clinicopathological features similar to those of NAFLD in humans. Our aim was to investigate the changes in liver histology in gal3(-/-) mice by long-term observation.
METHODS: We initially investigated three 15-month-old gal3(-/-) mice, of which two developed multiple liver nodules with dysplastic changes. Then, we histopathologically examined the liver specimens of the 15-, 20- and 25-month-old gal3(-/-) mice and attempted to evaluate the liver morphology by contrast enhanced computed tomography (CT) before sacrifice.
RESULTS: At the age of 15 months or later, gal3(-/-) mice developed liver nodules with varying degrees of architectural and nuclear atypia based on mild to moderate delicate zone 3 fibrosis. In addition, we successfully confirmed the presence of some of the liver nodules by CT. We report herein that gal3(-/-) mice develop dysplastic liver nodules and HCC.
CONCLUSIONS: We believe that it would be interesting to use this murine model to investigate liver carcinogenesis based on a natural history of NAFLD. Furthermore, CT scanning might be a useful tool for longitudinal evaluation of morphological changes in vivo.

Entities:  

Year:  2008        PMID: 18637146     DOI: 10.1111/j.1872-034X.2008.00395.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  14 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver.

Authors:  Ichiro Onoyama; Atsushi Suzuki; Akinobu Matsumoto; Kengo Tomita; Hideki Katagiri; Yuichi Oike; Keiko Nakayama; Keiichi I Nakayama
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

Review 3.  Genetically modified mouse models for the study of nonalcoholic fatty liver disease.

Authors:  Perumal Nagarajan; M Jerald Mahesh Kumar; Ramasamy Venkatesan; Subeer S Majundar; Ramesh C Juyal
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

4.  Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis.

Authors:  Ilija Jeftic; Nemanja Jovicic; Jelena Pantic; Nebojsa Arsenijevic; Miodrag L Lukic; Nada Pejnovic
Journal:  Mol Med       Date:  2015-05-22       Impact factor: 6.354

5.  Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function.

Authors:  Davina H Rhodes; Maria Pini; Karla J Castellanos; Trinidad Montero-Melendez; Dianne Cooper; Mauro Perretti; Giamila Fantuzzi
Journal:  Obesity (Silver Spring)       Date:  2013-02       Impact factor: 5.002

6.  Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis.

Authors:  Hwei-Fang Tsai; Chien-Sheng Wu; Yi-Lin Chen; Hsiu-Jung Liao; I-Tsu Chyuan; Ping-Ning Hsu
Journal:  J Mol Med (Berl)       Date:  2015-12-02       Impact factor: 4.599

Review 7.  Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.

Authors:  María L Bacigalupo; Malena Manzi; Gabriel A Rabinovich; María F Troncoso
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

8.  Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease.

Authors:  Kazuhiro Nomoto; Takeshi Nishida; Yuko Nakanishi; Makoto Fujimoto; Ichiro Takasaki; Yoshiaki Tabuchi; Koichi Tsuneyama
Journal:  ScientificWorldJournal       Date:  2012-04-19

9.  Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.

Authors:  Joanna K Dowman; Laurence J Hopkins; Gary M Reynolds; Nikolaos Nikolaou; Matthew J Armstrong; Jean C Shaw; Diarmaid D Houlihan; Patricia F Lalor; Jeremy W Tomlinson; Stefan G Hübscher; Philip N Newsome
Journal:  Am J Pathol       Date:  2014-03-17       Impact factor: 4.307

10.  Therapy of experimental NASH and fibrosis with galectin inhibitors.

Authors:  Peter G Traber; Eliezer Zomer
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.